TrialHaematologica2016

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase.

Massimo Breccia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.